Alnylam (ALNY) Q2 2023: TTR Franchise Grows 46% as Pipeline and Roche Partnership Expand Future Optionality
Alnylam delivered a multidimensional quarter, with TTR franchise surging 46% and the Roche partnership setting up a new hypertension platform. The business advanced late-stage pipeline assets, expanded global reach, and maintained a disciplined approach to expenses, all while navigating competitive and regulatory complexity. The company’s evolving product mix and new CNS data reinforce its transition from rare disease specialist to broader biotech innovator.
Summary
- TTR Franchise Drives Expansion: Ambutra and Onpatro uptake accelerated patient growth and global market penetration.
- Pipeline Optionality Broadens: Roche partnership and CNS data signal new revenue vectors beyond rare disease.
- Execution Focus Shifts: Leadership transitions and R&D milestones point to a more innovation-centric operating model.
Business Overview
Alnylam is a biotechnology company specializing in RNA interference (RNAi) therapies, generating revenue from four commercial products targeting rare and ultra-rare diseases: Onpatro and Ambutra for transthyretin-mediated amyloidosis (TTR), Givlar for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1. The core business model leverages proprietary RNAi technology to develop first-in-class and best-in-class medicines, with revenue split across its TTR franchise and ultra-rare product lines, supplemented by collaboration and royalty income.
Performance Analysis
Alnylam’s total product revenue rose 33% year-over-year, with the TTR franchise (Onpatro and Ambutra) contributing the majority of growth. Ambutra, launched in the US in Q3 2022, continued to drive both patient switches and new patient starts, expanding the prescriber base by almost 50% in its first year and supporting a fourth consecutive quarter of over 70% TTR growth in the US. Internationally, Japan and the UK saw robust Ambutra demand, while Onpatro maintained relevance in markets awaiting Ambutra launch.
The ultra-rare segment, comprising Givlar and Oxlumo, grew 37% year-over-year, reflecting the company’s ability to sustain growth in small populations through global reach and compliance initiatives. Gross margin declined to 75%, primarily due to fees from canceling Onpatro manufacturing commitments, as Ambutra takes share. R&D and SG&A expenses rose 11% and 14% respectively, reflecting investment in pipeline and launch capabilities, but top-line leverage improved operating loss modestly. Cash reserves remain strong at $2.1 billion, supporting the company’s self-sustainability roadmap.
- Ambutra-Driven Mix Shift: Ambutra’s adoption is accelerating patient growth and franchise expansion, offsetting Onpatro declines in switched markets.
- Ultra-Rare Portfolio Resilience: Givlar and Oxlumo growth underscores commercial execution in small, global patient pools.
- Margin Compression: Inventory and manufacturing adjustments for Onpatro signal ongoing product transition costs.
Overall, Alnylam is executing on both commercial and pipeline fronts, balancing near-term franchise expansion with investments in new indications and platforms.
Executive Commentary
"We continue to make great progress across our business...the Ambutra launch once again drove strong growth in our TTR franchise with 46% year-over-year growth and in total product sales with 43% year-over-year growth."
Yvonne, Chief Executive Officer
"Our non-GAAP operating loss for the quarter was $154 million, representing a $7 million improvement compared with Q2 2022, driven by strong top-line growth, offset by more moderate growth in operating expenses."
Jeff Fulton, Chief Financial Officer
Strategic Positioning
1. TTR Franchise Evolution
Alnylam’s TTR franchise is rapidly transitioning from Onpatro to Ambutra, with Ambutra now the growth engine in key markets. The company’s ability to manage patient switches, expand prescriber reach, and drive high compliance (over 90%) is central to sustaining franchise momentum. Strategic focus on securing access and reimbursement, especially in new geographies, is supporting global expansion.
2. Pipeline Diversification and CNS Entry
Positive interim data from ALN-APP in early Alzheimer’s disease marks a significant entry into CNS therapeutics, validating the RNAi platform’s broader applicability. The company is leveraging this proof-of-concept to pursue additional CNS targets, with preclinical work on Huntington’s (HTT) and ALS (SOD) programs underway. This diversification could unlock new addressable markets and revenue streams.
3. Roche Partnership and Hypertension Platform
The strategic alliance with Roche for Zalbisiran in hypertension brings $310 million upfront and up to $365 million in near-term milestones, with Roche funding 60% of development costs. This partnership de-risks capital requirements, while positioning Alnylam for a potential paradigm shift in hypertension treatment. The collaboration also reflects a shift toward larger, non-rare indications.
4. Leadership and R&D Model Shift
The transition of Akshay Vajnall to Chief Innovation Officer signals a deliberate focus on pipeline discovery and long-term R&D productivity. Alnylam is strengthening its innovation engine, aiming to sustain a high-yielding pipeline and support its “fifth by 25” goal of becoming a top-tier biotech.
5. Regulatory and Market Access Navigation
Alnylam successfully closed a US Attorney’s Office case with no action, reinforcing its commitment to compliance. The company is preparing for a pivotal FDA advisory committee (adcom) for Patisiran in ATTR cardiomyopathy, with data submissions and expanded access programs underscoring clinical and commercial readiness.
Key Considerations
Alnylam’s Q2 reflected a company balancing rapid franchise growth, pipeline expansion, and operational discipline. Management is navigating product transitions, regulatory hurdles, and competitive signals while investing in new platforms and geographies.
Key Considerations:
- Ambutra Uptake Pace: Sustained US and international adoption is key to TTR revenue trajectory and margin stabilization as Onpatro wanes.
- Pipeline Milestone Cadence: Upcoming data from Helios B, Cardia-1/2, and CNS programs will determine future growth vectors and investor confidence.
- Roche Partnership Economics: Cost-sharing and milestone structure reduce capital intensity, but execution risk remains on large-scale hypertension trials.
- Regulatory Inflection Points: FDA decisions on Patisiran and future label expansions will shape competitive positioning and market access.
Risks
Key risks include regulatory delays or negative outcomes for Patisiran and other late-stage assets, competitive threats from emerging therapies (including generics and new modalities), and operational challenges in scaling CNS and hypertension programs. Margin pressure from product mix shifts and launch investments may persist, while macroeconomic or reimbursement headwinds could impact international growth.
Forward Outlook
For Q3 2023, Alnylam guided to:
- Combined net product revenues of $1.2 to $1.285 billion for the full year across four commercial products
- Collaboration and royalty revenue of $100 to $175 million for the full year
Management reiterated expense guidance for R&D and SG&A between $1.575 and $1.65 billion. Upcoming catalysts include the FDA adcom for Patisiran, top-line data from Cardia-1 and Cardia-2, and further CNS data, with Roche partnership milestones expected as development progresses.
- Ambutra launch and patient growth remain central to near-term results
- Pipeline data and regulatory events will drive sentiment into 2024
Takeaways
Alnylam’s quarter demonstrated robust commercial execution and a strategic pivot toward platform and pipeline optionality. The TTR franchise remains the anchor, but new partnerships and CNS progress are broadening the company’s future revenue base.
- Franchise Expansion: Ambutra’s rapid uptake and global reach are sustaining growth even as the product mix shifts and Onpatro declines in major markets.
- Pipeline and Partnership Optionality: The Roche alliance and CNS advances position Alnylam for expansion beyond rare disease, but execution risk is rising as the company scales into broader indications.
- Investor Watchpoint: Monitor regulatory outcomes, Ambutra’s international ramp, and CNS/hypertension clinical milestones for inflection signals over the next 12 months.
Conclusion
Alnylam’s Q2 2023 confirms its evolution from rare disease leader to innovation-driven biotech, with commercial momentum, pipeline breadth, and strategic partnerships providing multiple avenues for future growth. Execution on upcoming regulatory and clinical milestones will determine the company’s trajectory as it seeks to balance growth, margin, and risk in a more complex operating landscape.
Industry Read-Through
Alnylam’s results reinforce the commercial potential of RNAi therapeutics in both rare and broader indications, with the Roche partnership highlighting large pharma appetite for platform deals and cost-sharing in high-risk, high-reward categories. The company’s ability to transition patients between products, maintain high compliance, and expand prescriber bases offers a playbook for other rare disease biotechs facing product lifecycle transitions. Emerging CNS data and hypertension platform moves signal an industry shift toward applying RNA-based modalities beyond traditional orphan markets, with regulatory navigation and payer engagement remaining critical for successful scale-up.